The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the bindin
The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.
대표청구항▼
1. An antibody formulation comprising: a) about 20 mg/mL of a humanized IgG4 anti-CXCR5 (C-X-C chemokine receptor type 5) antibody comprising a heavy chain variable region comprising complementary determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOS: 15, 16, and 17, and a lig
1. An antibody formulation comprising: a) about 20 mg/mL of a humanized IgG4 anti-CXCR5 (C-X-C chemokine receptor type 5) antibody comprising a heavy chain variable region comprising complementary determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOS: 15, 16, and 17, and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOS: 18, 19, and 20;b) about 10 mM citrate buffer;c) about 0.02% polysorbate 20;d) about 6% sucrose; ande) about 0.2% sodium chloride; wherein the pH of the formulation is at or below the lower of about pH 6.0 and the pI of the binding agent. 2. An antibody formulation comprising: a) about 100 mg/mL of a humanized IgG4 anti-CXCR5 (C-X-C chemokine receptor type 5) antibody comprising a heavy chain variable region comprising complementary determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOS: 15, 16, and 17, and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOS: 18, 19, and 20;b) about 10 mM citrate buffer;c) about 0.01% polysorbate 20;d) about 4.5% sucrose;e) about 0.2% sodium chloride; andf) about 1% arginine; wherein the pH of the formulation is at or below the lower of about pH 6.0 and the pI of the binding agent. 3. An antibody formulation comprising: a) about 5 mg/mL to about 280 mg/mL of a humanized IgG4 anti-CXCR5 (C-X-C chemokine receptor type 5) antibody comprising a heavy chain variable region comprising complementary determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOS: 15, 16, and 17, and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NOS: 18, 19, and 20;b) about 10 mM citrate buffer;c) about 0.01% polysorbate 20;d) about 4.5% sucrose;e) about 0.2% sodium chloride; andf) about 1% arginine; wherein the pH of the formulation is at or below the lower of about pH 6.0 and the pI of the binding agent. 4. The formulation of claim 3, wherein the formulation is a liquid formulation. 5. The formulation of claim 3, wherein the formulation is a lyophilized formulation. 6. The formulation of claim 3, wherein 5% or less of the binding agent in the formulation forms aggregates. 7. The formulation of claim 3, wherein a monomer of the antibody has a purity of about 90%. 8. The formulation of claim 3, wherein the antibody has a biological activity of at least about 90% of the biological activity exhibited at the time the formulation was prepared, as determined in an antigen binding assay. 9. The formulation of claim 3, wherein the humanized IgG4 anti-CXCR5 (C-X-C chemokine receptor type 5) antibody is present in an amount of from about 5 to about 25 mg/mL, from about 26 to about 50 mg/mL, from about 51 to about 75 mg/mL, from about 76 to about 100 mg/mL, from about 101 to about 125 mg/mL, from about 126 to about 150 mg/mL, from about 151 to about 175 mg/mL, from about 176 to about 200 mg/mL, from about 201 mg/mL to about 225 mg/mL, from about 226 mg/mL to about 250 mg/mL, or from about 251 to about 280 mg/mL. 10. A kit comprising a container comprising: 1) the formulation of claim 3, and 2) a label or instructions for the administration and use of the formulation. 11. A pre-filled device or pre-filled container comprising the formulation of claim 3. 12. The pre-filled device of claim 11, wherein the pre-filled device comprises a pre-filled syringe or a pre-filled autoinjector. 13. The pre-filled container of claim 11, wherein the pre-filled container comprises a sealed ampoule, a vial, a bottle, a test tube, a cartouche, or a sachet.
Lynch, Carmel M.; Burstein, Haim; Stepan, Anthony M.; Lockert, Dara H., Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors.
Chari Ravi V. J. (Newton MA) Goldmakher Viktor S. (Newton MA) Blattler Walter A. (Brookline MA), Cell binding agent conjugates of analogues and derivatives of CC-1065.
Parenteau Nancy Louise ; Johnson Eric William ; Meunier Susan Frances ; Maresh John Gregory, Chemically defined cell culture media and system and methods for use, particularly for culturing epithelial cells.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Shenk Thomas E. (Princeton NJ) Samulski Richard J. (Pittsburgh PA) Chang Long-Sheng (Linden NJ), Helper-free stocks of recombinant adeno-associated virus vectors.
Boguslaski Robert C. (Elkhart IN) Carrico Robert J. (Bremen IN) Christner James E. (Ann Arbor MI), Heterogenous specific binding assay employing a cycling reactant as label.
Kucherlapati Raju (Darien CT) Koller Beverly H. (Carrboro NC) Smithies Oliver (Chapel Hill NC), Homologous recombination for universal donor cells and chimeric mammalian hosts.
Cunningham Brian C. (Piedmont CA) Lowman Henry (Hercules CA) Wells James A. (Burlingame CA), Human growth hormone variants having greater affinity for human growth hormone receptor at site 1.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Loetscher Marcel,CHX ; Moser Bernhard,CHX ; Qin Shixin ; Mackay Charles R., IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor.
Morgan Jeffrey R. (Brighton MA) Mulligan Richard C. (Cambridge MA), In vivo introduction and expression of foreign genetic material in epithelial cells.
Mather Jennie P. (Millbrae CA) Tsao Mary C. (Burlingame CA), Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins.
Freedman Bernard (Peoria IL) Powell Richard G. (Peoria IL) Smith ; Jr. Cecil R. (Dunlap IL), Method of controlling the European corn borer with trewiasine.
Kauffman Stuart Alan ; Ballivet Marc,CHX, Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and co.
Morrison Sherie L. ; Herzenberg Leonard A. ; Oi Vernon T., Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
Robinson Randy R. ; Liu Alvin Y. ; Horwitz Arnold H. ; Better Marc ; Wall Randolph ; Lei Shau-Ping ; Wilcox Gary L., Modular assembly of antibody genes, antibodies prepared thereby and use.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Kauffman Stuart Alan ; Ballivet Marc,CHX, Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides.
Kauffman Stuart Alan ; Ballivet Marc,CHX, Process for the production of stochastically-generated peptides,polypeptides or proteins having a predetermined propert.
Griffiths Andrew David,GBX ; Hoogenboom Hendricus Renerus Jacobus Mattheus,GBX ; Marks James David ; McCafferty John,GBX ; Winter Gregory Paul,GBX ; Grigg Geoffrey Walter,AUX, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Pedersen Jan T. (Bath GBX) Searle Stephen M. J. (Bath GBX) Rees Anthony R. (Bath GBX) Roguska Michael A. (Ashland MA) Guild Braydon C. (Concord MA), Resurfacing of rodent antibodies.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.